SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...

Hundreds of people in England with aggressive blood cancer are set to benefit from an innovative new treatment that ...

My annual scan showed no cancer recurrence, but revealed some minor issues related to aging and potential fibroids, requiring ...

The FDA has approved a new three-drug combination to treat certain types of an aggressive blood cancer called large B-cell lymphoma (LBCL).

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

CAR T-cell therapy showed efficacy in relapsed large B-cell lymphoma across age groups, including patients 70 and 80 years or older.

Northeast Ohio cancer survivor Samantha Skowron feels immense gratitude towards St Jude Children's Research Hospital for many reasons. Diagnosed with Hodgkin's Lymphoma at the age of 14, Samantha is ...